The potentiality of ruxolitinib for CSF3R T618I-mutated patients was demonstrated with two case reports: a 75-years old man and a 11-years old girl with aCML. Here, CSF3R is linked to atypical chronic myeloid leukemia, BCR-ABL1 negative.